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Objective. To evaluate diagnostic utility of Dishevelled-3 (DVL-3) mRNA and δ-catenin mRNA expression in pleural eﬀusions of
patients with lung cancer. Methods.D V L - 3m R N Aa n dδ-catenin mRNA levels were assessed by performing RT-PCR on pleural
eﬀusion specimens from patients with lung cancer (n = 75) and with lung benign disease (n = 51). Results. The expressions
of DVL-3 mRNA and δ-catenin mRNA were signiﬁcantly higher in malignant than in benign lung disease (P<0.01) and were
obviously higher than cytology in adenocarcinoma (P<0.01). Insingle use, DVL-3mRNAhad the highestspeciﬁcity (94.1%)and
PPV (95.7%), whereas δ-catenin mRNA had the highest sensitivity (92.0%) and NPV (88.5%). When combinations of markers
were evaluated together, DVL-3 mRNA and δ-catenin mRNA gave a high-diagnostic performance: sensitivity of 100.0%, NPV
of 100.0%, and accuracy of 96.0%, respectively. Conclusion. As molecular markers of detecting pleural micrometastasis, DVL-3
mRNA and δ-catenin mRNA are helpful to diagnose the cancer cells in pleural eﬀusions of patients with lung cancer.
1.Introduction
Pleural eﬀusion is a common clinical complication produced
by a wide variety of diseases. Approximately 20% of pleural
eﬀusions are due to malignancy, and 50% of these are due to
primary lung cancer [1]. A malignant pleural eﬀusion may
be the initial presentation of cancer in 10 to 50% of patients
[2]. The cytologic diagnosis of pleural eﬀusions can be
diﬃcultandusuallydetectonly50–60%ofmalignantpleural
eﬀusions [3], especially in specimens containing abundant
reactive mesothelial cells. Distinguishing carcinoma cells
from reactive mesothelial cells in such ﬂuid are particularly
challenging when there are relatively few carcinoma cells [4].
Additional techniques, such as immunocytochemistry and
enzyme-linked immunosorbent assay, provide signiﬁcant
help in this diﬀerential diagnosis [5, 6]. So far, many tumor
markers directed against speciﬁc cell type antigens have been
usedinpleuraleﬀusionstoenhancethecytologicaldiagnosis,
with varying degrees of eﬃcacy [7, 8], but the optimum
paneloftumormarkersstillhastobereported.Moreover,the
deﬁnition of earlier diagnosis of pleural eﬀusions of patients
withlungcancerbymeansofdetectingtumormarkermRNA
in occult lung cancer cells had previously been reported in
our studies [9, 10].
DVL-3 belongs to Dishevelled (Dvl) family proteins
which are cytoplasmic mediators of the Wnt/beta-catenin
signaling pathway and have recently been proved to be over-
expressed in nonsmall cell lung cancer (NSCLC), especially
in adenocarcinomas [11]. δ-catenin is a component of the
synaptic adherens junction that is necessary for normal
learning and memory [12] .A sam e m b e ro ft h ep 1 2 0
catenin (p120ctn) subfamily, δ-catenin is the only one that
its primary expression is restricted to the brain. However, in
recent years δ-catenin has shown overexpression in human
lung cancer and has proved a useful marker in diﬀerentiating
a malignant from a benign origin, the eﬀects of δ-catenin2 Clinical and Developmental Immunology
Table 1: Sequences and features of the primers used for RT-PCR.
Names Sequence of sense and antisense of primers Melting temperature Length
DVL-3 5 - AACCAGGGGGTTATGATAGCTC-3 
5 - TATCTCCTGGCTCGATGCGTCC- 3  57◦C 387bp
δ-catenin 5 -TACTCCGCAAGACGACTGACC-3 
5 -CCATCACACTCTCTCATCCTTCTG-3  57◦C 284bp
β-actin 5 -TGGCACCCAGCACAATGAA −3 
5 -CTAAGTCATAGTCCGCCTAGAAGCA −3  55◦C 186bp
bp: base pairs.
expression in lung cancer still need to be clariﬁed [13,
14].
The main purpose of this study was to determine the
diagnostic capacity in pleural eﬀusions of tumor markers
DVL-3 mRNA and δ-catenin mRNA. In particular, we
evaluate the value of DVL-3 mRNA and δ-catenin mRNA
in diﬀerentiating the pleural eﬀusions of patients with lung
cancer from those of patients with benign lung disease.
2.MaterialsandMethods
2.1. Patients. The study was conducted in accordance with
the regulations of the institutional review boards at China
Medical University and was performed at The First Aﬃliated
Hospital, China Medical University. Internal review board
approval for this study and/or the informed consent of
the patients was obtained. A total of 126 pleural eﬀusion
samples collected from the patients at the Laboratory of
Cytopathology of the First Aﬃliated Hospital of China
Medical University from May 2010 to June 2011 were
included in this study. There were 68 males (54%) and 58
females (46%). Samples consisted of 75 malignant eﬀusions
and 51 benign eﬀusions. The eﬀusions were classiﬁed as
benign or malignant on the basis of their deﬁnite pathologic
diagnosis.
A total of 51 eﬀusions were deﬁned as benign includ-
ing parapneumonic (26) and tuberculosis (25) and 75 as
adenocarcinoma. Of the 51 patients with benign eﬀusion,
38 were men (74.5%) and 13 were women (25.5%), with a
mean age of 61.4 years (range, 20–84). Of the 75 patients
with malignant eﬀusion, 30 were men (40.0%) and 45 were
women (60.0%), with a mean age of 60.1 years (range, 29–
80).
The eﬀusions were considered malignant if malignant
cells were found on cytologic examination or in a biopsy
specimen. Only specimens diagnosed as primary malignan-
cies of lung or pleura were considered; malignancies of any
other cause were excluded.
Tuberculous pleurisy was diagnosed if one of the fol-
lowing criteria was met: identiﬁcation of bacillus in pleural
ﬂuid or biopsy specimen cultures; the presence of caseous
granulomas in pleural biopsy tissue; radiological and clinical
evidence of tuberculous pleurisy with acid-fast bacilli-
positive sputum, followed by response to antituburculous
therapy.
Parapneumonic pleurisy was determined when there was
an acute febrile illness with purulent sputum, pulmonary
inﬁltrate, and responsiveness to antibiotic treatment or
identiﬁcation of the microorganism in the pleural eﬀusion
in the absence of any other cause associated with pleural
eﬀusions.
2.2. Preparation of Cells from Pleural Eﬀusions. All specimens
were received as fresh eﬀusion, with a volume range of 20–
2,000mL. The specimens were centrifuged for 30 minutes
at 2,000rpm at 4◦C. The resulting pellet was used for
the preparation of two cytological smears (alcohol ﬁxed,
Papanicolau stained), and the rest of the pellet was stored at
−70◦C until being used for RNA extraction.
2.3. RT-PCR Analysis. Total RNA Extraction. Total RNA
was extracted from the cell pellet using Trizol Reagent
(Gibco, Life Technologies; Rockville, MD) according to the
manufacturer’s instruction. Then, total RNA was diluted
in RNase-free water and quantiﬁed by measurement of
absorbance at 260 and 280nm. The range of OD260/OD280
of extraction of total RNA from all the specimens is 1.82–
2.01.
Reverse transcription was done with the TaKaRa RNA
PCR KIT (AMV) Ver.3.0 (TaKaRa; Lianxing Bio, Dalian,
China). Following the manufacture’s instructions, total RNA
(0.5ug) was converted to ﬁrst-strand cDNA in 10-uL
reaction mixture, which contains 1uL 0.5g/l total RNA,
2uL 25mmol/L MgCl2,1 u L1 0× RT buﬀer, 1uL 10 ×
dNTP mixture (10mM each), 0.25uL RNase inhibitor,
0.5uL 5U/uL AMV (Avain Myeloblastosis Virus) Reverse
Transcriptase, 0.5uL. 0.5g/l Oligo dT-Adaptor Primer, and
3.75uL RNase-free dH2O, at 42◦C for 30 minutes, 99◦C
for 3 minutes, and 5◦C for 5 minutes. PCR was done
in 50-ul reaction mixture containing 4-uL cDNA, 31.7-
uL ddH2O, 10uL 5 × PCR buﬀer, 4uL for both sense
and antisense primers of DVL-3, δ-catenin, and β-actin,
0.3 uL 5 U/uL TaKaRa EX Taq HS. Primers of β-actin were
used to check RNA intergrity and the eﬃciency of the
reverse transcription step. The primers sequences, melting
temperature, and expected length of synthesis fragments
were shown in Table 1. After a denaturing step at 94◦C
for 2 minutes, PCR was done at 94◦C for 30 seconds, at
57◦C for 40 seconds, and at 72◦C for 40 seconds for 35
cycles. PCR products were separated by electrophoresis on
8% polyacrylamide gels, followed by staining with AgNO3,
as shown in Figure 1. The whole-test analysis was performed
without any knowledge of the patients’ clinical ﬁndings.Clinical and Developmental Immunology 3
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Figure 1: RT-PCRampliﬁed productsofDVL-3,δ-catenin, and β-actininpleuraleﬀusions of patients with lung cancer and benign diseases.
The 387, 284, and 186bp DNA fragments were expected to be ampliﬁed from DVL-3, δ-catenin, and β-actin cDNAs, respectively. Lane M
represented DNA marker (50–500bp). Lanes 1, 2, 3, 6 and 7 represented pleural eﬀusion of patients with lung cancer, respectively. Lanes 4
and 5 represented pleural eﬀusion of patients with benign diseases, respectively.
Table 2: Results for DVL-3 mRNA, δ-catenin mRNA expression by RT-PCR and for cytological assessment in pleural eﬀusions of patients
with benign or malignant lung lesions.
Group n DVL-3 mRNA δ-catenin mRNA Cytology
+ − + − + −
Pneumonia 26 2 24 4 22 0 26
Tuberculosis 25 1 24 1 24 0 25
Adenocarcinoma 75 67∗§ 86 9 ∗§ 64 4 3 1
∗P<0.01 as compared to pneumonia and tuberculosis. §P<0.01 as compared to cytology. (i) The DVL-3 mRNAs were positively correlated with δ-catenin
mRNA (r = 0.743). Date are number of specimens.
2.4. Quality Control. The nucleotide sequence of PCR prod-
uct was subcloned and sequenced by dideoxy chain termina-
tionandconﬁrmedtobe100%homologoustohumanDVL-
3a n dδ-catenin. A GenBank database search veriﬁed that the
sequences are speciﬁc to DVL-3 and δ-catenin.
2.5. Statistical Analysis. Statistical analysis was performed
using the χ2 test or Fisher’s exact test when theoretical
eﬀectiveness was insuﬃcient. The level of statistical signiﬁ-
cance was set at P<0.05. The utility of each marker was
determined by means of sensitivity, speciﬁcity, PPV, NPV,
and accuracy. Diagnostic performance of the combination
of DVL-3 mRNA and δ-catenin mRNA was calculated in
parallel text. Calculations for combinations of DVL-3 mRNA
and δ-catenin mRNA were assessed as “positive” if RT-PCR
result was seen with either or both positive results and
“negative” if both were negative.
3. Results
The results of DVL-3 mRNA expression, δ-catenin mRNA
expression, and cytological assessment of pleural eﬀusion
specimens from patients with adenocarcinoma, parapneu-
monic, and tuberculosis are presented in Table 2.B o t hD V L -
3m R N Aa n dδ-catenin mRNA were signiﬁcantly more likely
to be expressed in malignant than in benign lung disease
(P<0.01), and the expressions of DVL-3 mRNA and δ-
catenin mRNA were more likely to be positive than cytology
in adenocarcinoma (P<0.01). Moreover, the expression
of DVL-3 mRNA was positively correlated with δ-catenin
mRNA (r = 0.743).
Table 3 shows the results obtained by cytological assess-
ment as compared with those obtained by RT-PCR or
histology, for pleural eﬀusions from patients with benign
lung disease and with adenocarcinoma. There were sig-
niﬁcantly fewer false negative results by RT-PCR than by
cytology because RT-PCR facilitates the detection of few or
single carcinoma cells in pleural eﬀusion specimens. Twenty-
seven and thirty specimens gave false-negative results by
cytology but positive results by detecting DVL-3 mRNA and
δ-catenin mRNA, respectively; these were ﬁfteen specimens
with suspected cancer cells and twelve specimens with
reactive mesothelial cells by detecting DVL-3 mRNA, and
eighteen specimens with suspected cancer cells and twelve
with reactive mesothelial cells by detecting δ-catenin mRNA,
respectively. There were two specimens with pneumonia
and one specimen positive for tuberculosis that gave false-
positive results by detecting DVL-3 mRNA, and four
specimens with pneumonia and one specimen positive for
tuberculosis that gave false-positive results by detecting δ-
catenin mRNA, respectively.
Table 4 shows the sensitivity, speciﬁcity, PPV, NPV, and
accuracy of DVL-3 mRNA, δ-catenin mRNA, combinations
of DVL-3 mRNA and δ-catenin mRNA, and cytology, with
respect to the histological diagnosis of lung cancer. In single,
DVL-3 mRNA had the highest speciﬁcity (94.1%) and PPV
(95.7%), whereas δ-catenin mRNA had the highest sensi-
tivity (92.0%) and NPV (88.5%). When combinations of
DVL-3mRNAandδ-cateninmRNAwereevaluatedtogether,
DVL-3 mRNA and δ-catenin mRNA gave a high- diagnostic
performance: sensitivity of 100.0%, NPV of 100.0%, and
accuracy of 96.0%, respectively. These were evidently higher
than in single use and cytology. Although speciﬁcity (90.2%)
and PPV (93.8%) were lower for combinations of DVL-3
mRNAandδ-cateninmRNAthanforcytology(100%),there
were no statistical signiﬁcant in these diﬀerences (P>0.05).4 Clinical and Developmental Immunology
Table 3: Results obtained by cytological assessment as compared with those obtained by RT-PCR for DVL-3 mRNA and δ-catenin mRNA
or by histology in pleural eﬀusions specimens from patients with benign or malignant lung lesions.
Cytology Total DVL-3 mRNA δ-catenin mRNA Histology
n + − + − + −
P n e u m o n i a 4 023 843 604 0
T u b e r c u l o s i s 1 111 011 001 1
RMC 13 12 1 12 1 13 0
Suspected to be malignant 18 15 3 18 0 18 0
Adenocarcinoma cells 44 40 4 39 5 44 0
Total 126 70 56 74 52 75 51
Date are number of specimens. RMC: reactive mesothelial cells.
Table 4: Accuracy of RT-PCR for detection of DVL-3 mRNA, δ-catenin mRNA and combination of them compared with cytology for the
diagnosis of lung cancer.
Variables Single Combination of Cytology
DVL-3 δ-catenin DVL-3 plus δ-catenin
Sensitivity (%) 89.3 92.0 100.0∗ 58.7
Speciﬁcity (%) 94.1 90.2 90.2 100.0
Accuracy (%) 91.3 91.3 96.0∗ 75.4
PPV (%) 95.7 93.2 93.8 100.0
NPV (%) 85.7 88.5 100.0∗ 62.2
PPV: positive predictive value; NPV: negative predictive value; ∗P<0.01 comparing RT-PCR of combination group with cytology.
4. Discussion
Morphological diﬀerentiation of reactive mesothelial cells
from carcinoma cells in pleural eﬀusions can be a diag-
nostic challenge. Adenocarcinoma metastatic to the pleural
membrane is often associated with prominent mesothelial
hyperplasia and may result in diagnostic confusion. The
diﬃculty is obviously greater when neoplastic cells show
only slight atypia or when they are scarce in the eﬀusion
[7]. False-negative results of cytological examination of
pleural ﬂuid are a serious problem. Such errors in diagnosis
usually are caused by misinterpretation of adenocarcinoma
cells as reactive mesothelial cells [4]. The rate of false-
positive diagnoses also is signiﬁcant and often caused by
overinterpretation of reactive mesothelial cells as malignant
cells [15]. Immunocytochemistry can greatly aid in such
diagnostic dilemmas, but, currently, available markers have
varying sensitivities and speciﬁcities for mesothelial cell or
cells of epithelial diﬀerentiation [16, 17]. Recently, we have
evaluatedRT-PCRtechniquesforthedetectionofcancercells
in pleural eﬀusions of patients with lung cancer and have
demonstrated that these techniques are more sensitive than
immunocytochemistry [9, 10].
DVL-3 is a member of the human dishevelled family,
located on chromosome 3q27 [18], is abnormally expressed
in nonsmall cell lung cancer, and aﬀect lung cancer cell
invasiveness and metastasis [11]. δ-catenin belongs to the
p120-catenin protein family, located on chromosome 5p15.2
[19] and contains a ten-armadillo repeat domain,which has
47% similarity to that of p120ctn [20]. The mRNA and
protein expression of δ-catenin was increased in lung cancer
tissues and its positive expression rate was signiﬁcantly
increased in adenocarcinoma, stages III-IV, paired lymph
node metastasis lesions, and primary tumours with lymph
node metastasis [13], but little is known about the positive
expression rate in pleural eﬀusions from patients with lung
cancer and the correlation between DVL-3 and δ-catenin.
Identiﬁcation of molecular markers for disease progres-
sion would be of great clinical value. RT-PCR is a sensitive
method that can objectively detect even one cancer cell
among 106 cells [21, 22]. In the present study, the expression
frequencies of DVL-3 mRNA and δ-catenin mRNA were
signiﬁcantly greater in the adenocarcinoma group (P<0.01)
compared with the benign lung disease group. The rate of
positive diagnosis was signiﬁcantly greater by RT-PCR than
by cytology in the adenocarcinoma group. Moreover, the
expression of DVL-3 mRNA was positively correlated with
δ-catenin mRNA (r = 0.743). Twenty-seven and thirty
specimens gave false-negative results by cytology but positive
results by detecting DVL-3 mRNA and δ-catenin mRNA,
respectively; these were ﬁfteen specimens with suspected
cancer cells and twelve specimens with reactive mesothelial
cells by detecting DVL-3 mRNA, and eighteen specimens
withsuspectedcancercellsandtwelvewithreactivemesothe-
lial cells by detecting δ-catenin mRNA, respectively. False-
negative results on cytological examination may be due to
cells that are only slightly atypical or to a scarcity of cells
in pleural eﬀusions of patients with lung cancer. AlthoughClinical and Developmental Immunology 5
all eighteen specimens with suspicious cytology contained
malignant cells and were positive by detecting δ-catenin
mRNA, atypical cytology was not necessarily associated with
malignancy, even when δ-catenin mRNA was positive. Three
and ﬁve specimens gave false-positive results by detecting
DVL-3 mRNA and δ-catenin mRNA, respectively, giving
a PPV of 95.7% and 93.2%, as compared with 100% by
cytology. Therefore, DVL-3 mRNA and δ-catenin mRNA
are sensitive molecular markers for the diagnosis of lung
cancer.
At present, there is an obvious limitation in the interna-
tionalTNMstagingofnonsmallcelllungcarcinomathatwas
absent from the interpretation of occult tumor cells [23, 24].
Additionally, the inclusion of the interpretation of occult
micrometastases in the current TNM staging system is also
recommended by the International Union Against Cancer
[25]. Thus, detecting DVL-3 mRNA and δ-catenin mRNA in
a pleural eﬀusion can provide a supplement to TNM staging.
In conclusion, RT-PCR detection of DVL-3 mRNA and
δ-catenin mRNA showed better diagnostic performance
compared with cytology, especially when combinations of
DVL-3 mRNA and δ-catenin mRNA were evaluated together
with a sensitivity of 100% and an NPV of 100%. These
ﬁndings suggest that detection of DVL-3 mRNA and δ-
catenin mRNA in pleural eﬀusions from patients with lung
cancer could possibly be used as ancillary tools for the
diagnosisoflungcancer.Thissensitive,accurate,noninvasive
method may be helpful as a complementary tool that will
facilitate the establishment of a diagnosis of lung cancer.
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